ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

peginterferon alfa-2b

Also written as “Peginterferon alfa-2b”, “peginterferon alfa-2b (SCH 54031)” and “PEG-Intron”.

Its studies are mostly in Hepatitis C, Chronic · Hepatitis C · Hepatitis B, Chronic · Melanoma · Hepatitis B, led by 4 companies.

Drug pagePeginterferon alfa-2b: every studyAll 139 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Nov 15, 200552 company-led studies, 2 open or runningNext primary completion: May 31, 2029

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merckits history only450 open or runningphase 4since Nov 15, 2005Mar 29, 2000none ahead
Tanabe Pharmaits history only30 open or runningphase 3since Nov 2, 2011Feb 24, 2008none ahead
Xiamen Amoytop Biotech32 open or runningphase 3since Apr 12, 2021Apr 12, 2021May 31, 2029NCT06707922
FGK Clinical Researchits history only10 open or runningphase 4since Jul 11, 2006Jul 11, 2006none ahead

Also a collaborator on its studies: Vertex Pharmaceuticals, Integrated Therapeutics Group, Johnson & Johnson and ViroPharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Xiamen Amoytop Biotech only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 12, 2021First study: phase 3 study in Hepatitis B, ChronicFirst studyNCT04846491 · 475 enrolled · China
  2. Jul 27, 2024Phase 2 study in Thrombocythemia, EssentialNCT06552429 · 27 planned · China
  3. Nov 24, 2024No phase study in Hepatitis B, ChronicNCT06707922 · 350 planned · China

Ahead

  1. May 31, 2029Primary completion: no phase study in Hepatitis B, ChronicNCT06707922

TargetBeta

“Interferon alpha/beta receptor agonist”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
peginterferon alfa-2aruleHoffmann-La Rochephase 4100
Interferon beta-1aruleBiogenphase 460

Studies

All 3 Xiamen Amoytop Biotech leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06707922Hepatitis B, Chronic · China–By invitationMay 31, 2029350
NCT06552429Thrombocythemia, Essential · China2RecruitingOct 26, 202527
NCT04846491Hepatitis B, Chronic · China3CompletedNov 30, 2023475

How it is read

Names in the registry

  • “Peginterferon alfa-2b”, 10 entries
  • “peginterferon alfa-2b (SCH 54031)”, 5 entries
  • “PEG-Intron”, 4 entries
  • “PegIntron (peginterferon alfa-2b)”, 4 entries
  • “Peginterferon alfa-2b injection”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.